Skip to content
Ankylosing Spondylitis News logo
  • Ankylosing Spondylitis News on Facebook
  • About ankylosing spondylitis
    What is ankylosing spondylitis?
    Symptoms
    Diagnosis
    Living with AS
  • Treatments
    Approved treatments
    Experimental treatments
  • News
  • Columns
    The Recalibrated Compass — Alexandra Fendrich
    Archived columns
    • A Wellness Journey — Lisa Marie Basile
    • Joint Journey – Jemma Newman
    • Just Keep Swimming — Janneke Phung
    • Kicking AS — Andrea Wyckoff
  • What can we help you find today?

    • Ankylosing Spondylitis News on Facebook

February 13, 2020 News by Marisa Wexler MS

Health Canada Approves Taltz for Treatment of Active Ankylosing Spondylitis

Health Canada approved Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS) who have responded poorly to or are unable to tolerate conventional therapies. Eli Lilly‘s Taltz is a disease-modifying antirheumatic drug (DMARD) that works by blocking the activity of interleukin-17A, a…

December 16, 2019 News by Marisa Wexler MS

AS Patients on Taltz Treatment Experienced Less Fatigue and Pain, and Better Sleep Over 1 Year, Phase 3 Trials Show

Treatment with Taltz (ixekizumab) reduces fatigue and pain in people with ankylosing spondylitis (AS) for up to one year, results from two Phase 3 trials show. The data were discussed at the 2019 American College of Rheumatology/Association for Rheumatology Professionals Annual Meeting in a presentation, titled…

July 11, 2019 News by Jose Marques Lopes PhD

Ixekizumab Eases Pain and Fatigue, Improves AS Patients’ Quality of Life, Phase 3 Trials Show

Under-the-skin treatment with ixekizumab leads to early and sustained reductions in pain, fatigue, and inflammation, as well as significant improvements in sleep and quality of life, as reported by patients with ankylosing spondylitis (AS) who took part in two Phase 3 trials. The research, “Translating Improvements…

November 5, 2018 News by Catarina Silva, MSc

Ixekizumab Benefits Ankylosing Spondylitis Patients Who Failed to Respond to Standard Therapy, Phase 3 Study Shows

Ankylosing spondylitis (AS) patients who have failed to respond to standard therapy may benefit from treatment with ixekizumab (Taltz by Eli Lilly), Phase 3 study results show. The study, “Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a…

March 5, 2018 News by Alice Melao

Ixekizumab Shows Promise in Phase 3 Trial of Radiographic Axial Spondyloarthritis

Treatment with the monoclonal antibody Taltz (ixekizumab) significantly reduced the symptoms of radiographic axial spondyloarthritis (rad-axSpA) in patients participating in a Phase 3 clinical trial, early data show. The study, called COAST-V (NCT02696785), met its primary and all key secondary endpoints, therapy developer Eli Lilly said in a…

Recent Posts

  • Ankylosing spondylitis community set to ‘Lace Up’ for World AS Day April 28, 2025
  • Finding strength and community through connection with others April 15, 2025
  • FDA approves Cortrophin Gel for use in prefilled syringes March 10, 2025
  • FDA agrees to review application for Simponi biosimilar February 10, 2025
  • Reflecting on 2024 and setting intentions for the new year January 28, 2025


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

  • Ankylosing Spondylitis News on Facebook
Copyright © 2013-2025 All rights reserved.